FDA OKs use of rotavirus vaccines, add contraindication

The Food and Drug Administration (FDA) determined on May 14 that it is appropriate for U.S. clinicians and public health providers to resume the use of Rotarix (Glaxo SmithKline Biologicals) and to continue the use of RotaTeq (Merck & Co. Inc.) rotavirus vaccines. In addition, a contraindication